PROCOL BIOLOGIC VASCULAR GRAFT HJL016-40-N

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,health report with the FDA on 2020-02-19 for PROCOL BIOLOGIC VASCULAR GRAFT HJL016-40-N manufactured by Lemaitre Vascular, Inc..

Event Text Entries

[185004755] We have received the explanted graft for evaluation. However, we were unable to investigate the returned graft. The graft has already decayed by the time of our device evaluation since it was returned to us without being submergerd in sterile solution. We have also received a picture of the reported defect from the surgeon. In the provided picture, we observed the proximal end of the graft had dilated twice the diameter of its distal section. The procol graft is a natural vein with competent valves. As stated in the ifu, the beveled cut end is the inflow end of the vessel. The graft should not be implanted or flushed in the opposite direction of flow as competent valves may cause excessive pressure and damage the integrity of the vessel. Our inquiry with the implanting physician revealed that he believed that he had implanted the device in the correct orientation. But the picture provided conflicted with that description. Therefore, we are not conclusive on the exact root cause of this failure. Our review of the lot history records for this lot did not find any discrepancies either in the manufacturing or packaging process that could be related to this incident. Further, we have not received any other complaints of a similar nature for devices from this lot. Hence, we consider this to be an isolated incident. Please note that each graft is pressurized between 2. 7-4. 0 psi ( 139 - 206 mmhg) during the inspection process. If pressure exceeds 4 psi, the vessel is rejected for 'overpressurized' and discarded. Under a pressurized condition, each graft is inspected by the manufacturing operators for any presence of hole, tear or swelling. An od gage is passed over the entire length of the vessel. If any section of the graft appeared to be dilated or did not pass through the gage smoothly, then that section of the graft is rejected by the technician. Each graft is again inspected by the qc technician for these attributes. Physician implanted another procol vascular graft without any issue.
Patient Sequence No: 1, Text Type: N, H10


[185004756] Surgeon used a procol vascular bioprosthesis for creating a bridge graft for vascular access in a dialysis patient. After completion of arterial anastomosis, when surgeon removed the clamp and the graft was under arterial pressure, he observed the proximal end of the graft had dilated.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number1220948-2020-00021
MDR Report Key9729589
Report SourceCOMPANY REPRESENTATIVE,HEALTH
Date Received2020-02-19
Date of Report2020-02-19
Date of Event2020-01-20
Date Mfgr Received2020-01-20
Device Manufacturer Date2019-08-27
Date Added to Maude2020-02-19
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMR. PRAGYA THIKEY
Manufacturer Street63 SECOND AVE
Manufacturer CityBURLINGTON, MA
Manufacturer CountryUS
Manufacturer Phone2212266152
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NamePROCOL BIOLOGIC VASCULAR GRAFT
Generic NameVASCULAR GRAFT,
Product CodeLXA
Date Received2020-02-19
Returned To Mfg2020-01-28
Model NumberHJL016-40-N
Catalog NumberHJL016-40-N
Lot NumberPVB1044
OperatorHEALTH PROFESSIONAL
Device AvailabilityR
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerLEMAITRE VASCULAR, INC.
Manufacturer Address63 SECOND AVE BURLINGTON, MA US


Patients

Patient NumberTreatmentOutcomeDate
10 2020-02-19

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.